Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis
Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis
The purpose of this study is to determine the effect of AZD1236 in patients with cystic
 fibrosis (CF) on inflammatory biomarkers in induced sputum, after a treatment period of 4
 weeks.
Inclusion Criteria:

 -  Provision of informed consent prior to any study specific procedures

 -  Have a clinical diagnosis of cystic fibrosis with an FEV1 >40% of predicted normal

 -  Be able to comply with induced sputum procedure

 -  post-menopausal surgically sterile female (total hysterectomy and /or bilateral total
 oophorectomy)

 Exclusion Criteria:

 -  Concomitant diagnosis of significant pulmonary disease other than CF-related lung
 disease, including symptomatic asthma and allergic bronchopulmonary aspergillosis

 -  Treatment with any immunomodulatory agents within 8 weeks prior to Visit 2

 -  Known to be infected with Burkholderia cepacia